Kristine Peterson joined Valeritas as Chief Executive Officer in June 2009. Valeritas is a medical technology company that develops and commercializes innovative new products, with its lead product being the V-Go™ disposable insulin delivery device targeted specifically for Type 2 diabetics. Ms. Peterson brings nearly 30 years of industry experience to Valeritas, with her most recent previous position as Company Group Chair for Johnson & Johnson’s multi-billion dollar worldwide biotech and oncology groups. During her tenure, she launched two blockbuster products, licensed and acquired important new treatments, progressed the oncology and immunology pipeline, and ensured quality standards within her global biologics manufacturing group. Prior to her 5 years at J&J, Ms. Peterson was Senior Vice President, Commercial Operations for Biovail Corporation. Earlier, she spent 20 years at Bristol Myers-Squibb where she held assignments of increasing responsibility, including running a cardiovascular/metabolics business unit that generated $6 billion in revenue and a generics business.